# LifeCare Partners

> LifeCare Partners is a VC fund in Basel backing Biotechnology and Medical. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Basel, Switzerland
- Total investments: 11
- Last investment: Mar 2026
- Lead investor: 64%
- Last updated: Aug 2026
- Website: http://www.lifecarevc.com

LifeCare Partners is a VC fund in Basel focused on Biotechnology and Medical. LifeCare Partners provides private equity and mezzanine financing

## Contacts

5 contacts available for LifeCare Partners. Shizune tracks 1 team members at LifeCare Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lifecare-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $4.1M–$19M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 45% |
| Medical | 4 | 36% |
| Health Care | 4 | 36% |
| Software | 2 | 18% |
| Medical Device | 2 | 18% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 45% |
| Funding Round | 2 | 18% |
| Post-IPO Equity | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 3 | 27% |
| Switzerland | 2 | 18% |
| United States | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gerhard Ries | General Partner | 10 | https://shizune.co/investors/profile/gerhard-ries |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kupando | Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $11.5M | Series A | Mar 18, 2026 |  |
| Kupando | Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $12.5M | Series A | Sep 26, 2022 |  |
| b-rayZ | b-rayZ is a spin-off of the University Hospital Zurich. Their team consists of professional radiologists, data scientists and physicians, with more than 15 years of work experience in medical imaging and radiology. They develop and provide predictive deep learning analytical tools and algorithms for the assessment of your personal medical images. | $4.1M | Series A | Jul 07, 2022 |  |
| NeoPrediX | NeoPrediX develops decision support tools with maternal, neonatal and perinatal screening platforms to evaluate, optimize and personalize medical strategies in pediatrics. We utilize intelligent algorithms and digital health solutions for neonatal and perinatal care based on deep medical data and science, developed by experienced scientists,pediatricians, and neonatologists. We transform medical data into intelligent predictions to support clinical decisions. | $4.8M |  | Mar 17, 2021 |  |
| NeoPrediX | NeoPrediX develops decision support tools with maternal, neonatal and perinatal screening platforms to evaluate, optimize and personalize medical strategies in pediatrics. We utilize intelligent algorithms and digital health solutions for neonatal and perinatal care based on deep medical data and science, developed by experienced scientists,pediatricians, and neonatologists. We transform medical data into intelligent predictions to support clinical decisions. | $4.4M | Series A | Mar 17, 2021 |  |
| Immunic Therapeutics | Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $11M | Series A | Sep 05, 2017 |  |
| Immunic Therapeutics | Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. |  | Series A | Feb 01, 2017 |  |
| Immunic Therapeutics | Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $19.2M | Series A | Sep 27, 2016 |  |
| Kuros Biosciences | Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed fromwork carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology.Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. The company is in transition to commercial stage with one product having marketing approval in the EU and US and further product expected to achieve EU approval this year. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, a putty formulation is being prepared for submission in the EU and the US in the second half of this year. Neuroseal, a novel biomaterial for dural sealing, is Kuros’ second product and currently under review for CE marking in the EU.Kuros has also assembled a pipeline of clinical stage programs in various stages of development and amassed significant clinical and preclinical data in a number of indications and applications primarily in the area of orthobiologics. The Company has enrolled over 600 patients in multinational clinical trials, and has generated promising safety and efficacy in a number of significant indications. | $15.4M | Post-IPO Equity | Aug 18, 2015 |  |
| leon nanodrugs | leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. |  | Series A | Jul 27, 2015 |  |

10 of 11 investments shown.

## Co-investors
- [Bayern Kapital](https://shizune.co/investors/profile/bayern-kapital) — VC Fund, 4 deals together
- [Eckenstein-Geigy-Stiftung](https://shizune.co/investors/profile/eckenstein-geigy-stiftung) — VC Fund, 3 deals together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 3 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 3 deals together
- [Brandenburg Kapital](https://shizune.co/investors/profile/bfb-brandenburg-kapital-gmbh) — VC Fund, 2 deals together
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Medical Investors in Germany](https://shizune.co/investors/medical-investors-germany)
- [Medical Device Investors in Germany](https://shizune.co/investors/medical-device-investors-germany)
- [Medical Device VC Funds in Germany](https://shizune.co/investors/medical-device-vc-funds-germany)

## FAQ

### What does LifeCare Partners invest in?

LifeCare Partners invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Funding Round stage. Most of the 11 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is LifeCare Partners's check size?

LifeCare Partners typically joins rounds of $4.1M–$19M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds LifeCare Partners participates in.

### How do I contact LifeCare Partners?

Public channels for LifeCare Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LifeCare Partners?

The team at LifeCare Partners includes Gerhard Ries (General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co